Lilly Announces Results From OA Pain Relief Study

Posted: Updated:
(Image courtesy of Lilly) (Image courtesy of Lilly)

Pfizer Inc. (NYSE:PFE) and Indianapolis-based Eli Lilly and Co. (NYSE:LLY) have announced positive results from a Phase 3 study evaluating an osteoarthritis relief medication. Lilly says the medication was found to deliver a statistically significant improvement in pain, physical function and the patients’ overall assessment.

In the study, tanezumab was administered in 2.5 mg or 5 mg and evaluated every eight weeks, for a total of 24 weeks, in patients with moderate-to-severe OA pain. Tanezumab is an antibody that is part of a class of non-opioid pain medications known as nerve growth factor inhibitors.

Participants in the study had experienced inadequate pain relief from or intolerance to at least three different medications and most has been coping with OA for about six years. They reported that OA caused a disruption in their everyday life.

Tanezumab was generally successful in the 24-week treatment period. The trial also included a 24-week safety follow-up period, for a total of 48 weeks of observation.

 “For many people, living with osteoarthritis pain can limit their ability to function, which can force them to make compromises in everyday life,” said Christi Shaw, president, Lilly Bio-Medicines in a news release. “Lilly and Pfizer have a shared commitment to advance the care of people living with chronic pain, and we see the potential of tanezumab as an innovative, non-opioid option to improve the treatment of osteoarthritis pain, a debilitating, progressive condition.”

For more information, click here

  • Perspectives

    • Owe Taxes? What Went Wrong in 2018 and How to Survive It

      The 2018 tax filing deadline came and went. Whew! But for some Americans, the tax headache has just begun. This year was the first filing under the Tax Cuts and Jobs Act and while some taxpayers saw larger refunds others received a rude awakening. If you’re reeling from a large tax burden, this article is for you. The Root of the Problem Remember how excited you were when you received your first paycheck—followed by dismay when you saw how much was taken out for taxes.



Company Name:
Confirm Email:
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections


  • Most Popular Stories

    • Photo of Gary City Hall courtesy of the City of Gary

      McDermott Details Gary Retail Desert

      The city of Gary is facing challenges as it tries to rejuvenate retail business in the city. In an interview with our partners at The Times of Northwest Indiana, Aaron McDermott, president of Latitude Commercial Real Estate Services in Schererville, says the challenge is due to the perception, proximity and demographics associated with Gary. 

    • The Landing project involves redeveloping seven buildings and two parking lots into a mixed-use development.

      New Restaurant Concept Coming to The Landing

      The developers of a $34 million redevelopment project in downtown Fort Wayne have announced a new partnership. Cincinnati-based The Model Group says it is working with Cunningham Restaurant Group to bring a "new and unique" restaurant experience to The Landing.

    • Ball State Among '30 Best Online MBA Degree Programs'

      Ball State University’s Miller College of Business has been recognized as one of The 30 Best Online MBA Degree Programs by MBA Central. The website details 30 programs across the nation and praises Ball State’s program for its variety and affordability.

    • Ryan Wagoner

      Profit With a Purpose: The Rise of Social Impact Investing

      Social impact investing is a fast-growing sector driven by investors who want to use private capital to further the public good. This industry provides a unique opportunity for results-oriented social entrepreneurs to invest in businesses, funds and nonprofits with the intention of generating positive, measurable social change alongside financial return. By engaging in impact investing, investors can align their investment portfolios with their philanthropic priorities.

    • Lilly and Avidity Biosciences Announce Partnership

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Avidity Biosciences Inc. have announced a new partnership. The global licensing and research collaboration will work toward the discovery, development and commercialization of new medicines in immunology and other areas.